Table 1.

Cytosine methylation levels of bone marrow mononuclear cells from patients treated with decitabine

Patient no.Sample collection% 5mCSD
4001pre-DAC4.40.2
post-DAC14.00.3
post-DAC24.10.1
post-DAC53.20.3
post-DAC62.70.3
12 months post-DAC63.80.2
post-2 DAC13.60.1
post-2 DAC23.40.2
4013pre-DAC3.70.2
post-DAC13.60.1
post-DAC23.30.3
post-2 DAC22.70.2
post-2 DAC51.30.2
4016pre-DACn.d.n.d.
post-DAC13.70.2
post-DAC23.70.1
6 months post-DAC64.20.3
15 months post-DAC63.90.2
post-2 DAC23.40.2
post-2 DAC63.40.2
6 months post-2 DAC64.20.1
4019pre-DAC3.60.3
post-DAC63.60.3
4029pre-DAC4.10.3
post-DAC63.30.3
5 months post-DAC64.10.3
4034pre-DAC3.50.2
post-DAC23.70.1
post-DAC42.10.1
post-DAC60.90.1
2 months post-DAC63.00.2
4035pre-DACn.d.n.d.
post-DAC23.80.3
post-DAC42.90.1
post-DAC62.00.1
6 months post-DAC83.50.2
  • NOTE: Numbers before DAC indicate treatment cycles, numbers after DAC indicate treatment courses. Follow-up samples (months post-DAC6) were collected from relapsed or remitted patients. Cytosine methylation levels (% 5mC) were determined by capillary electrophoretic analysis and calculated by dividing the fluorescence signal of 5-methylcytosine through the sum of fluorescence signals for cytosine plus 5-methylcytosine. n.d., not determined.